Capricor Therap
CAPR----
Capricor Therap (CAPR)
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treati...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Capricor Therap Analyst Rating
View MoreForecast & Rating
Jul 24, 2026Price forecast
$53.60172.08%
Forecast & RatingStrong buy
10analysts
- Strong buy80.00%
- Buy20.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Global Report · 7 hours ago
Biotech Regulatory Clearances and Edge AI Pivots Prompt Capital Reallocation Across US Equities
- Global Report · 1 day ago, 04:13 AM
The Fragmentation of Innovation: Why Niche Markets Matter This Summer
- Market Beat · 1 day ago, 01:00 PM
Stock Traders Purchase Large Volume of Call Options on Capricor Therapeutics (NASDAQ:CAPR)
- Global Report · 2 days ago, 04:13 AM
The 2026 Biotech Divide: When Generative Biology Meets the FDA Wall
- benzinga_article · Jul 9 at 12:35 PM
9 Health Care Stocks With Whale Alerts In Today’s Session
- PUBT · Jun 29 at 08:30 PM
Capricor CFO Anthony Bergmann disposes of USD 732,158 in common shares
